BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.6%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$10.2B
AUM Growth
+$10.2B
(+8.4%)
Cap. Flow
+$197M
Cap. Flow
% of AUM
1.92%
Top 10 Holdings %
Top 10 Hldgs %
30.33%
Holding
228
New
12
Increased
78
Reduced
41
Closed
15
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$72M |
| 2 |
Tandem Diabetes Care
TNDM
|
$48M |
| 3 |
IQVIA
IQV
|
$42.6M |
| 4 |
Adaptive Biotechnologies
ADPT
|
$39.3M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$39M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$238M |
| 2 |
Moderna
MRNA
|
$62.9M |
| 3 |
Cigna
CI
|
$45.4M |
| 4 |
Bristol-Myers Squibb
BMY
|
$41.5M |
| 5 |
DaVita
DVA
|
$39.6M |
Sector Composition
| 1 | Healthcare | 96.41% |
| 2 | Industrials | 0.94% |
| 3 | Technology | 0.31% |
| 4 | Financials | 0.04% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
HCA Healthcare
HCA
$95.4B
| $69.1M | 0.67% |
334,273
-40,290
| -11% | -$8.33M |
|
52
Generation Bio
GBIO
$40.3M
| $66.7M | 0.65% |
2,478,180
+85,000
| +4% | +$2.29M |
|
53
Scholar Rock
SRRK
$3.3B
| $66.4M | 0.65% |
2,297,625
+166,500
| +8% | +$4.81M |
|
54
Charles River Laboratories
CRL
$7.99B
| $65.9M | 0.64% |
178,270
-10,115
| -5% | -$3.74M |
|
|
SILK
55
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $61.9M | 0.6% |
1,293,759
+134,835
| +12% | +$6.45M |
|
56
Hologic
HOLX
$14.7B
| $61M | 0.6% |
913,752
| – | – |
|
|
57
Cigna
CI
$80.2B
| $60.9M | 0.59% |
256,742
-191,420
| -43% | -$45.4M |
|
58
Omnicell
OMCL
$1.51B
| $59.6M | 0.58% |
393,583
+65,664
| +20% | +$9.94M |
|
|
59
Regeneron Pharmaceuticals
REGN
$59.8B
| $59M | 0.58% |
105,660
+69,860
| +195% | +$39M |
|
60
Revolution Medicines
RVMD
$7.43B
| $58.9M | 0.57% |
1,854,805
+789,035
| +74% | +$25M |
|
61
Pacific Biosciences
PACB
$378M
| $57.5M | 0.56% |
1,643,159
+25,654
| +2% | +$897K |
|
62
Globus Medical
GMED
$7.94B
| $56.6M | 0.55% |
729,420
+81,911
| +13% | +$6.35M |
|
63
Bio-Rad Laboratories Class A
BIO
$7.8B
| $56.2M | 0.55% |
87,301
-12,901
| -13% | -$8.31M |
|
64
Veeva Systems
VEEV
$44.4B
| $53.7M | 0.52% |
172,647
+19,847
| +13% | +$6.17M |
|
65
Exelixis
EXEL
$9.95B
| $53.4M | 0.52% |
2,932,000
-12,500
| -0.4% | -$228K |
|
66
Molina Healthcare
MOH
$9.6B
| $50.3M | 0.49% |
198,734
-6,500
| -3% | -$1.64M |
|
67
Penumbra
PEN
$10.5B
| $49.9M | 0.49% |
182,125
+2,250
| +1% | +$617K |
|
|
ABMD
68
DELISTED
Abiomed Inc
ABMD
| $47.2M | 0.46% |
151,178
+8,494
| +6% | +$2.65M |
|
69
Guardant Health
GH
$8.11B
| $47.1M | 0.46% |
379,609
+76,743
| +25% | +$9.53M |
|
70
10x Genomics
TXG
$1.66B
| $45.6M | 0.44% |
232,672
+3,633
| +2% | +$711K |
|
71
Zimmer Biomet
ZBH
$20.8B
| $45M | 0.44% |
280,082
| – | – |
|
72
Medtronic
MDT
$118B
| $44.6M | 0.44% |
359,625
+27,103
| +8% | +$3.36M |
|
|
73
IQVIA
IQV
$31.4B
| $43M | 0.42% |
177,400
+175,600
| +9,756% | +$42.6M |
|
74
Teladoc Health
TDOC
$1.37B
| $42.9M | 0.42% |
257,948
+3,371
| +1% | +$561K |
|
75
Black Diamond Therapeutics
BDTX
$164M
| $42.2M | 0.41% |
3,463,000
+1,220,000
| +54% | +$14.9M |
|